2025 年 3 月 26 日 公司研究 临床前收入快速恢复，整体项目数稳步提升 ——药明生物（2269.HK）2024 年年报点评 研发技术能力强，对外授权增厚利润。公司多个技术平台赋能客户多样化需求， 目前管线内有 313 个 first-in-class 项目，151 个双抗/多抗项目以及 194 个 ADC 项目。公司 TCE 平台开发能力已得到多方认可，基于该平台开发的产品被授权 给默沙东/GSK 等海外公司，且 Medigene AG 也和公司达成战略研究服务合作， 开发 TCR-TCE 疗法。公司技术平台已赋能 50+具里程碑付款及销售分成潜力的 项目，R 技术平台有权获得总额约为 1.4 亿美元的近期付款，潜在总交易金额超 过 23 亿美元，将增厚公司未来利润。 盈利预测、估值与评级：考虑到全球大分子 CDMO 竞争加剧，以及地缘政治影 响，下调 25-26 年归母净利润预测为 42.8/49.3 亿元（前值为 47.4/53.9 亿元， 分别下调 9.7%/8.5%），新增 27 年归母净利润预测为 57.5 亿元，对应 PE 为 23/20/17 倍。公司是我国大分子 CDMO 龙头，且技 ...

深夜利好！恒瑞医药与默沙东签订19.7亿美元独家 协议 扬子晚报网3月26日讯(记者范晓林实习生朱秋璇)3月25日晚间，中国创新药龙头恒瑞医药 （600276）(600276.SH)宣布与美国跨国药企默沙东(Merck&Co,Inc.股票代码：MRK)达成独家许可协 议，将其自主研发的产品a HRS-5346在大中华区以外的全球权益授予后者。 默沙东将获得HRS-5346在大中华地区以外的全球范围内开发、生产和商业化的独家权利。 公告显示，HRS-5346是一种在研的Lp(a)口服小分子抑制剂，目前正在中国进行二期临床试验。 Lp(a)升高是一种遗传决定的疾病，也是心血管疾病的独立危险因素。据统计，全球约有14亿人口Lp(a) 水平升高。 根据双方敲定的协议条款，在交易款项安排上，恒瑞医药可即刻收获2亿美元的首付款，后续还有 望凭借该项目特定的开发、监管以及商业化进展，获得不超过17.7亿美元的里程碑付款。 若 HRS-5346相关产品顺利获批上市，恒瑞医药还将基于其净销售额，按一定比例获取销售提成， 交易总额上限高达19.7亿美元。HRS-5346作为一款口服小分子Lp(a)抑制剂，目前正在中国国内积极开 ...

Core Viewpoint - HengRui Medicine has entered into a licensing agreement with Merck to develop and commercialize the HRS-5346 project, a significant move in the pharmaceutical industry targeting Lp(a) as a cardiovascular risk factor [1][2]. Group 1: Licensing Agreement Details - The agreement allows Merck exclusive rights to develop, produce, and commercialize HRS-5346 outside Greater China, with an upfront payment of $200 million and potential milestone payments of up to $1.77 billion, plus sales royalties [1]. - The agreement is expected to take effect in the second quarter, but the approval and milestone payment timelines for HRS-5346 remain uncertain [1]. Group 2: Lp(a) and Cardiovascular Disease - Elevated Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), affecting approximately 1.4 billion people globally, with traditional medications showing limited efficacy in lowering Lp(a) levels [2][3]. - Current treatments, including statins and PCSK9 inhibitors, have limited impact on Lp(a), necessitating the development of targeted therapies [2][3]. Group 3: HRS-5346 and Market Potential - HRS-5346 works by blocking the covalent binding of apolipoprotein(a) with low-density lipoprotein (LDL), significantly reducing Lp(a) levels and improving atherosclerosis risk [3]. - As an oral small molecule drug, HRS-5346 offers better patient compliance and has the potential to become a market breakthrough [3]. Group 4: Industry Trends and Competitors - The development of Lp(a) inhibitors signifies a shift in cardiovascular treatment from broad lipid-lowering strategies to precision-targeted therapies, with several companies, including Novartis and Eli Lilly, advancing their own Lp(a) targeting drugs [4]. - Other domestic companies such as Jingxin Pharmaceutical, Xinlitai, WuXi AppTec, and Shiyao Group are also exploring this target, currently in preclinical stages [4].

Core Viewpoint - The collaboration between Heng Rui Medicine and Merck marks a significant licensing agreement in the innovative drug sector, indicating a trend of increasing partnerships between multinational pharmaceutical companies and local biotech firms in China [1][2]. Group 1: Licensing Agreements - Heng Rui Medicine announced a licensing agreement with Merck for the oral small molecule project Lp(a), granting Merck exclusive rights to develop, produce, and commercialize the compound HRS-5346 outside Greater China [1]. - Merck will pay Heng Rui a $200 million upfront fee, with potential milestone payments related to development, regulatory, and commercialization reaching up to $1.77 billion [1]. - Heng Rui will also receive sales royalties based on the performance of HRS-5346 outside Greater China [1]. Group 2: Market Trends - There has been a notable increase in business development collaborations between multinational pharmaceutical companies and local innovative drug firms since the end of 2023, with several prominent projects emerging this year [1][2]. - The innovative drug sector in Hong Kong is experiencing a valuation expansion that may be stronger than that in A-shares, driven by higher R&D expenditure and overseas revenue proportions [3]. Group 3: Financial Performance - The overall net profit growth of the Hong Kong innovative drug sector has consistently outpaced that of A-shares since the first half of 2023, suggesting a favorable outlook for profitability [3]. - The sector is more sensitive to U.S. Treasury rates and benefits from overseas liquidity easing, which could enhance valuation levels [4]. - Companies in the Hong Kong innovative drug sector are perceived to have better cost-performance advantages, indicating greater potential for valuation elasticity [4]. Group 4: Company Developments - Heptares Therapeutics has entered a share subscription agreement with AstraZeneca, with a subscription price of $1.38 per share, representing a 37.2% premium over the closing price on the agreement date [6]. - Federal Pharmaceuticals has signed an exclusive licensing agreement with Novo Nordisk for UBT251, a triple agonist in early clinical development, with potential payments totaling up to $1.8 billion [7][8]. - Akeso reported a significant revenue increase of 4765.6% to approximately 156 million yuan, driven by a milestone collaboration agreement worth 900 million yuan [8]. - Hutchison China MediTech received conditional approval for its drug Tazemetostat in China, marking its first national regulatory approval [9]. - China Biologic Products announced positive interim results for its innovative drug Culmerciclib in a Phase III trial for breast cancer, with plans to submit a marketing application soon [10].

Core Insights - Heng Rui Medicine has entered into a significant licensing agreement with Merck for its oral small molecule project targeting lipoprotein(a), with an upfront payment of $200 million and potential milestone payments up to $1.77 billion [3][4] - The Hong Kong Stock Connect Innovation Drug ETF (159570) has seen substantial inflows, with net subscriptions exceeding 240 million yuan and a total of over 800 million yuan in the last 60 days, indicating strong investor interest in innovative drug companies [4][6] - The trend of Chinese innovative drug companies expanding overseas is accelerating, with at least 262 license-out transactions expected from 2020 to 2024, totaling over $150 billion [4][5] Company Developments - Heng Rui Medicine's licensing deal with Merck includes exclusive rights for global development, production, and commercialization outside Greater China for the drug HRS-5346 [3][4] - Other companies like United Pharmaceuticals and Innovent Biologics have also secured significant licensing agreements, indicating a broader trend in the industry [3][5] - The recent performance of stocks within the Hong Kong Stock Connect Innovation Drug ETF shows a mixed picture, with notable gains from companies like 3SBio and declines from companies like Yunnan Baiyao [3][4] Market Trends - The Hong Kong Stock Connect Innovation Drug ETF has reached a new high in shares, reflecting a doubling in size over the past month, driven by increased investor confidence [4][6] - The overall market for innovative drugs is expected to benefit from AI advancements, improved financing conditions, and potential fiscal support, which could enhance profit margins for these companies [4][6] - The ETF's composition highlights a strong focus on leading companies in the innovative drug sector, with over 68% of its weight in the top ten holdings [6][7]

Core Viewpoint - Heng Rui Medicine has signed a $1.97 billion licensing agreement with Merck for its Lp(a) oral small molecule project, HRS-5346, granting Merck exclusive rights for development, production, and commercialization outside Greater China [1][2]. Company Summary - The agreement includes an upfront payment of $200 million from Merck, with potential milestone payments not exceeding $1.77 billion, plus sales royalties based on net sales of HRS-5346 after market launch, totaling at least $1.97 billion for Heng Rui Medicine [1][2]. - HRS-5346 is currently undergoing Phase II clinical trials in China and has the potential to reduce Lp(a) levels in the blood by over 80%, addressing a global patient population of 1.4 billion suffering from cardiovascular diseases linked to elevated Lp(a) [1][2]. - Heng Rui Medicine has been actively pursuing overseas licensing as part of its international expansion strategy, with 13 innovative drugs already licensed abroad [2]. Industry Summary - In 2024, the total upfront payments for overseas licensing in China's biopharmaceutical industry are projected to reach $4.94 billion, surpassing the $3.77 billion in financing for innovative drug research and development in the first year [3]. - Upfront payments provide direct funding for research and development, reducing reliance on equity financing for pharmaceutical companies [3].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 25.00 [6][8][17] Core Insights - The company's revenue for 2024 is expected to increase by 21.3% to RMB 12.26 billion, with a net profit growth of 33.4%, exceeding expectations [1][6] - The oncology drug segment is projected to contribute 61.2% of the total product sales revenue in 2024, driven by strong performance from the core product Amelot, which is expected to see sales growth of 19.9% [2] - The company has established a partnership with Merck for the development and commercialization of a GLP-1 receptor agonist, which is expected to enhance its capabilities in the metabolic field [4] - The company is currently developing 40 innovative drugs, with several in late-stage clinical trials, indicating a promising pipeline for future growth [5] Financial Summary - The company's revenue is projected to grow from RMB 10.10 billion in 2023 to RMB 12.26 billion in 2024, with a compound annual growth rate (CAGR) of 21.3% [7][14] - Shareholder net profit is expected to rise from RMB 3.28 billion in 2023 to RMB 4.37 billion in 2024, reflecting a growth rate of 33.4% [7][14] - The gross margin is anticipated to improve by 1.2 percentage points, while sales and administrative expenses as a percentage of product sales revenue are expected to decrease [1][7] Product and Market Developments - The oncology drug business is expected to grow from approximately RMB 6.55 billion in 2024 to RMB 10.97 billion by 2027, with a CAGR of 18.8% [2] - The anti-infection drug revenue is projected to increase by 15.0% to RMB 1.46 billion in 2024, primarily driven by the strong sales of the hepatitis drug Hengmu [3] - The company has received multiple recommendations for its products in clinical guidelines, which is expected to support future sales growth [3]

Core Viewpoint - HengRui Medicine has entered into an exclusive licensing agreement with Merck for its Lp(a) oral small molecule project, HRS-5346, with a total transaction value of $1.97 billion [1]. Group 1: Licensing Agreement Details - The agreement grants Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 outside Greater China, with HengRui receiving an upfront payment of $200 million [1]. - HengRui is also eligible for up to $1.77 billion in milestone payments related to development, regulatory, and commercialization, along with sales royalties based on net sales if the product is approved [1]. Group 2: Clinical Background and Market Potential - HRS-5346 is currently undergoing Phase II clinical trials in China and targets elevated Lp(a) levels, which affect over 1.4 billion people globally and are an independent risk factor for atherosclerotic cardiovascular diseases [1]. - Targeting Lp(a) represents a significant breakthrough in the prevention and treatment of cardiovascular diseases [1]. Group 3: Strategic Implications for HengRui - This marks HengRui's first strategic collaboration with a major multinational company, enhancing its internationalization efforts [3]. - The transaction is expected to close in the second quarter of 2025, contingent upon regulatory approvals and customary conditions [3][4]. - HengRui's recent licensing activities have accelerated since the appointment of its Chief Strategy Officer in January 2023, indicating a shift towards more aggressive business development strategies [2].

有个事和你们说一下，昨天评论席我提到公众号自带的语音功能故意跳过敏感的句子不读，疑似ai涉敏自保。腾讯的小伙伴看到了，他们也很意外有这种 事，找我定位到了具体的内容，现在已经去查原因了。他和我说这不是设计好的功能，只是个意外。 还有我提到我有房性早搏，此早bo非彼早bo， 这是一种心律失常的 病症 ，有些读者想歪了，我每天早搏1万多下，我若是那个早bo一万多下，小老弟 24小时都得立那儿，根本下不来了好吗。 …… 今天市场最大的事还是小米配售425亿，配售价53.25港币，昨天是彭博社透露，今天是官宣公告。 新股民这几年配售这个词看到的少，其实就是增发股票募集资金，只不过熊市一般没人搞配售，售也售不出去，小米股价9港币的时候敢配售40亿 都要炸，现在行情好起来了，雷总壮着胆子向市场要425亿，比迪子前几天433亿的配售稍微低一点。 结果今天小米大跌6.3%，收盘53.4，比配售价高一丢丢。成交额718亿，史高天量。 那这是机构们不看好小米，抛弃小米了吗？不是的，因为就在另一边，投资者表达出的认购意向是小米425亿配售额的好几倍。也是彭博社的消 息，挂盘册上大约有200行，前20大投资者分配到的配售股票约2/3 ...

Core Insights - Jiangsu Hengrui Medicine Co., Ltd. has signed a collaboration agreement with Merck to license its oral small molecule drug targeting lipoprotein(a) (HRS-5346) for a payment of $200 million upfront [3][4] - The agreement allows Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 outside Greater China, with potential milestone payments reaching up to $1.77 billion and additional sales royalties based on performance [3][4] - HRS-5346 is currently undergoing Phase II clinical trials in China and targets elevated Lp(a) levels, which are linked to cardiovascular diseases [4][5] Financial Implications - The total potential revenue for Hengrui from this collaboration could approach $2 billion, including upfront payments, milestone payments, and sales royalties [3][4] - Hengrui has previously engaged in 12 licensing deals since 2018, totaling approximately $12 billion, with upfront payments around $400 million [4] Strategic Importance - This partnership is expected to enhance Hengrui's international market presence and improve its innovative brand and overseas performance [5] - The collaboration aligns with Hengrui's strategy of balancing in-house development with external partnerships to accelerate the global reach of its innovative products [5]